MiMedx Group (NASDAQ:MDXG). is a biopharmaceutical company specializing in the development, manufacture and commercialization of regenerative biomaterial products derived from human placental tissues. The company’s offerings address a broad spectrum of clinical needs, including chronic and acute wound care, orthopaedic and sports medicine, general surgery, and ophthalmology. MiMedx leverages proprietary purification and stabilization processes to preserve key biological components such as collagen, growth factors and cytokines, positioning its products as advanced solutions in regenerative medicine.
Core products in MiMedx’s portfolio include dehydrated amniotic membrane allografts, soft tissue repair matrices and injectable amniotic tissue formulations. These products are marketed under brands such as EpiFix, AmnioFix and Grafix, and are utilized by healthcare providers in hospital systems, outpatient wound care centers, physician offices and surgical centers. The company’s product pipeline also encompasses new indications in nerve regeneration, plastic surgery and sports medicine, reflecting its commitment to expanding the clinical applications of placental allografts.
Founded in 2008 and headquartered in Marietta, Georgia, MiMedx serves a domestic customer base spanning all 50 states, as well as select international markets through strategic partnerships and distributors. Over the years, the company has invested in manufacturing capacity, quality systems and regulatory compliance to support large-scale production and to meet the rigorous standards of the U.S. Food and Drug Administration. MiMedx’s supply chain infrastructure includes multiple FDA-registered processing facilities to ensure consistency and traceability of its tissue-based products.
MiMedx is led by a management team with deep experience in biotechnology, tissue allografts and commercial operations. The company’s founder, Parker H. Small, continues to influence its strategic direction, while a team of senior executives oversees research and development, regulatory affairs and global sales. With a focus on innovation, clinical evidence generation and physician education, MiMedx aims to advance the adoption of regenerative therapies and to address unmet medical needs across diverse patient populations.
